181 related articles for article (PubMed ID: 30753225)
1. SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing.
Mezzadra R; de Bruijn M; Jae LT; Gomez-Eerland R; Duursma A; Scheeren FA; Brummelkamp TR; Schumacher TN
PLoS One; 2019; 14(2):e0212053. PubMed ID: 30753225
[TBL] [Abstract][Full Text] [Related]
2. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
4. Evidence that knock down of GSK-3β in Chronic Myelogenous Leukemia cells augments IFN-γ-induced apoptosis.
Kauffman MR; Nazemidashtarjandi S; Ghazanfari D; Allen AE; Reynolds NM; Faik A; Burdick MM; McCall KD; Goetz DJ
Leuk Res; 2020 Dec; 99():106464. PubMed ID: 33130330
[TBL] [Abstract][Full Text] [Related]
5. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs.
Li M; Kao E; Malone D; Gao X; Wang JYJ; David M
Nat Struct Mol Biol; 2018 Nov; 25(11):1047-1058. PubMed ID: 30374083
[TBL] [Abstract][Full Text] [Related]
6. IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.
Zimmerman M; Yang D; Hu X; Liu F; Singh N; Browning D; Ganapathy V; Chandler P; Choubey D; Abrams SI; Liu K
PLoS One; 2010 Nov; 5(11):e14076. PubMed ID: 21124930
[TBL] [Abstract][Full Text] [Related]
7. Modulation of SLFN11 induces changes in DNA Damage response in breast cancer.
Raynaud CM; Ahmed EI; Jabeen A; Sanchez A; Sherif S; Carneiro-Lobo TC; Awad A; Awartani D; Naik A; Thomas R; Decock J; Zoppoli G; Bedongnetti D; Hendrickx WRL
Cancer Cell Int; 2023 Nov; 23(1):291. PubMed ID: 38001424
[TBL] [Abstract][Full Text] [Related]
8. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
9. Interferon-γ induces the cell surface exposure of phosphatidylserine by activating the protein MLKL in the absence of caspase-8 activity.
Chen J; Kuroki S; Someda M; Yonehara S
J Biol Chem; 2019 Aug; 294(32):11994-12006. PubMed ID: 31217278
[TBL] [Abstract][Full Text] [Related]
10. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
[No Abstract] [Full Text] [Related]
12. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
[TBL] [Abstract][Full Text] [Related]
13. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
[TBL] [Abstract][Full Text] [Related]
14. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
[TBL] [Abstract][Full Text] [Related]
15. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
16. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway.
Chaturvedi V; Bodner B; Qin JZ; Nickoloff BJ
J Dermatol Sci; 2006 Jan; 41(1):31-41. PubMed ID: 16289694
[TBL] [Abstract][Full Text] [Related]
17. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
19. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Murai J; Thomas A; Miettinen M; Pommier Y
Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
[TBL] [Abstract][Full Text] [Related]
20. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
